Table III.
Association between the increase of platelet per 50 × 109/L and mortality risk.
| Increase per 50 × 109/L over the whole range of platelet count | P value | Increase per 50 × 109/L
when platelets below 200 × 109/L |
P value | |
|---|---|---|---|---|
| No. of death/total | 49/383 | 44/261 | ||
| Crude model | 0.51 (0.38, 0.69) | <0.001 | 0.50 (0.33, 0.76) | 0.001 |
| Model 1 | 0.63 (0.46, 0.85) | 0.003 | 0.62 (0.40, 0.95) | 0.03 |
| Model 2 | 0.60 (0.43, 0.84) | 0.003 | 0.62 (0.39, 0.98) | 0.04 |
Data are presented as hazard ratios (HR) and 95% confidence intervals
Model 1 adjusted for age, sex, and baseline comorbidities (including chronic obstructive pulmonary disease, hypertension, diabetes, chronic kidney disease, cardiovascular disease, and cerebrovascular disease);
Model 2 adjusted for model 1, plus glucocorticoid therapy, intravenous immunoglobulin, blood lactate, C-reactive protein, and lymphocyte count.